The recent clinical success of CD19-directed chimeric antigen receptor (CAR) T cell therapy in chronic and acute leukemia has led to increased interest in broadening this technology to other hematological malignancies and solid tumors. Now, advances are being made using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, and kappa-light chain as well as CD19 on putative myeloma stem cells. To date, only a limited number of multiple myeloma patients have received CAR T cell therapy but preliminary results have been encouraging. In this review, we summarize the recently reported results of clinical trials conducted utilizing CAR T cell therapy in multiple myeloma (MM).
Introduction
Multiple myeloma (MM) is a hematologic malignancy defined by the accumulation of clonal plasma cells within the bone marrow, with evidence of end organ damage that can be attributed to the underlying plasma cell proliferative disorder. Evidence of disease includes lytic bone lesions and/or pathologic fractures, hypercalcemia, anemia, renal impairment, and increased susceptibility to opportunistic infections [1] . As of 2016, the incidence of MM has reached 5.6 per 100,000 persons and accounts for approximately 10% of all hematological malignancies in the This article is part of the Topical Collection on Multiple Myeloma
Western world [1, 2] . Traditionally, treatment of MM has focused on prolonging patient survival by reduction of malignant plasma cell burden followed by maintenance therapy. Recent insights into the pathophysiology of MM have led to the development of novel therapeutic agents, such as immune-modulatory drugs (e.g., lenalidomide, thalidomide, and pomalidomide) and proteasome inhibitors (e.g., bortezomib and carfilzomib). Over the last decade, these new agents have revolutionized disease management and dramatically improved survival in newly diagnosed patients [3] [4] [5] . When induction therapy utilizing these new agents is followed by autologous stem cell transplant (ASCT) and subsequent maintenance therapy, up to one-third of patients can achieve a complete response (CR) [3] . Despite these recent treatment advances, disease recurrence still remains a major obstacle, with nearly all patients eventually relapsing with increasingly refractory disease [6] . As MM remains an incurable disease, new treatment options are critical for these patients.
Chimeric Antigen Receptor T cells
The recent success of autologous CAR T cells transduced to express a chimeric antigen receptor (CAR) targeting CD19 in relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) [7, 8] and acute lymphoblastic leukemia (ALL) [9] [10] [11] has spurred new interest in broadening this technology to other hematological malignancies and solid tumors. CAR T cells are genetically modified to express an antigen receptor recognizing a tumor-associated surface antigen. Ideally, these tumorassociated antigens would be uniquely expressed by the malignant cells and absent on normal tissues. In this way, CAR T cells and their effector functions are re-directed towards specific malignant targets in an MHC-independent fashion.
Traditionally, CARs consist of an extracellular targeting region linked to various intracellular signaling domains. Targeting is achieved via a single-chain variable fragment (scFv) derived from a monoclonal antibody. The scFv is connected to the intracellular domains by a hinge/transmembrane region, commonly derived from CD8 or IgG4. The intracellular domains have conventionally consisted of either one (2 nd -generation CAR) or two (3 rd -generation CAR) co-stimulatory domains, e.g., 4-1BB, CD28, or OX-40 linked to the cytoplasmic signaling domain of CD3ζ. The CD3ζ domain alone is not sufficient to drive optimal T cell proliferation and cytokine production [12, 13] ; however, the incorporation of various co-stimulatory domains can result in increased CAR T cell signaling, persistence, and efficacy [14, 15] . The effect of various co-stimulatory domains on T cell function differs in accordance with their original function. 4-1BBζ-containing CARs have shown increased persistence and reduced exhaustion in vivo compared to CD28ζ CARs [14, 15] , whereas CD28ζ CARs display increased cytokine production and may result in different kinetics of expansion following antigen stimulation. Although CD28ζ CARs appear to have faster and more robust functionality initially, they lack the ongoing persistence compared to their 41BBζ counterparts [14] . So far, the use of 3 rd -generation CARs equipped with multiple costimulatory domains has not shown increased efficacy compared to that of second-generation CARs [14, 16] .
Limiting CAR T Cell-Related Toxicities
CAR-related toxicities can be divided into on-target, off-tumor effects and systemic toxicities. One of the major challenges in developing new CAR constructs is the identification of suitable and unique targets. Ideally, the target antigen should be tumorspecific and play a fundamental role in maintaining tumorogenicity in order to limit antigen escape, while also lacking expression on normal life-sustaining tissues. Beyond targetmediated toxicities, CAR T cells can also induce a systemic inflammatory syndrome termed cytokine release syndrome (CRS).
The issue of on-target, off-tumor effects naturally varies based on the chosen antigen. Given the power of CAR T cell therapy, targeting an antigen that is also expressed, even in low levels on normal tissues, can have fatal consequences [17] . The incorporation of a "suicide gene" into CAR T constructs allows for the elimination of CAR-modified T cells in the event of toxicity [18, 19] . Whether or not this approach will be beneficial depends on the depth and rapidity of CAR T cell elimination, as CAR T cell loss may take several days depending on the system used. Additional strategies include engineering CAR T cells to express specific chemokine receptors allowing direct homing to the tumor environment or minimizing trafficking to non-tumor sites [20, 21] . Co-inhibitory receptors (iCAR) are also being investigated in an attempt to spare healthy tissue in the event of CAR recognition [22] . This strategy is attractive, but requires identification of surface antigens that are only expressed on healthy tissue and not on tumor cells.
CRS is an increasingly recognized toxicity noted in various CAR T cell trials in hematologic malignancies. In most patients, CRS symptoms are mild and include flu-like symptoms such as fever and mild hypotension. In more severe cases, clinical features include hypotension, hypoxia, capillary leak, and coagulopathy all of which can potentially lead to fatal multi-organ dysfunction [23, 24] . The hallmark of CRS is immune activation as noted by dramatic elevations in pro-inflammatory cytokines, such as IL-6, IL-10, IFN-γ, and granulocyte macrophage-colony stimulating factor (GM-CSF) [17, 23, 24] . In general, the presence of CRS correlates with expansion and activation of CAR T cells; in ALL, but not lymphomas, the severity of CRS is associated with increasing disease burden. The incidence and severity of CRS in patients receiving CAR T cells for multiple myeloma has not yet been defined. Although the clinical outcome of CAR therapy cannot be predicted on the basis of CRS severity, the majority of patients who respond to therapy do experience some degree of CRS. One challenge following recognition of CRS has been choosing an appropriate therapy that dampens the uncontrolled inflammatory response without reducing CAR T cell efficacy. Traditionally, management of CRS consisted of systemic administration of glucocorticoids, though prolonged glucocorticoid administration (e.g., > 14 days) may also dampen or ablate the function of infused CAR T cells [9, 23] . Given the recognition of IL-6 as a primary mediator of CRS, newer approaches to management have targeted IL-6 itself with anti IL-6 receptor (IL-6R) antibodies such as tocilizumab [11, 23] . The effect of IL-6R blockade in relation to CAR T cell proliferation, persistence, and anti-tumor efficacy is still under investigation, but early data suggests that the use of anti-cytokine agents does not limit the anti-tumor efficacy of CAR T cells.
CARs in Clinical Trials for Multiple Myeloma
The interest in developing CARs that target MM has dramatically increased over the last few years. To date, the results of four clinical trials have been published and additional constructs are in development. The structure of these various CAR products differs with respect to targeted antigen, incorporation of co-stimulatory domains, and reported anti-tumor efficacy in clinical trials (Fig. 1) .
CD19
CAR T cells directed against CD19 have shown tremendous potential in hematological malignancies such as ALL and CLL [9, 11] . CD19 expression is not traditionally associated with MM and is generally not considered a therapeutic target in this disease [30] . Despite the lack of CD19 expression on the plasma cell clones, some studies have identified expression on a minor MM stem cell subset [31] making CD19 a potential target for eliminating recurrence following elimination of differentiated plasma cells. These MM stem cells have been associated with increased drug-resistance and are potentially responsible for the incurable nature of MM. This observation was the rationale for conducting a clinical trial using a CAR against CD19 [25••] . Garfall and Maus et al. described one patient treated with an anti-CD19-4-1BB-CD3ζ CAR T cell product (CTL019) [25••] . The patient underwent CTL019 infusion following high-dose melphalan and autologous stem cell transplant. Following infusion of CAR T cells, no fever or other signs of CRS were noted; however, CTL019 cells were detected in both blood and bone marrow for up to 47 days following infusion. The patient was started on lenalidomide maintenance treatment 3 months later, as per standard of care. Disease evaluation after 12 months demonstrated maintenance of a complete response (CR) to CTL019. This durable response was achieved despite the absence of CD19 expression on 99.95% of the patient's malignant cells.
At the annual meeting of the American Society of Hematology (ASH) in December 2016, investigators from U. Penn presented updated data from a safety and feasibility trial of MM patients treated with CTL019. In total, 12 patients were enrolled in the study with ten patients receiving infusion of CTL019 (5 × 10 7 CAR expressing T cells) 12-14 days after high-dose melphalan and ASCT. The treatment resulted in a median progression-free survival after ASCT + CTL019 of 185 days, with patients experiencing very good partial response (VGPR) (n = 6), partial response (PR) (n = 2), and progressive disease (PD) (n = 2). Overall, only minor adverse effects including mild CRS were observed and the product was well tolerated.
Although CD19 is expressed rarely on MM plasma cells, the presence of CD19 on a cancer stem cell-like population makes CD19 a potential target in combination with traditional therapies. Further studies are required to fully understand the mechanisms underlying the results reported in the CTL019 trials.
CD138
CD138, also known as syndecan 1, is a surface protein expressed on most healthy and malignant plasma cells [32] . CD138 functions as an adhesion protein, binding collagen and fibronectin molecules located in the extracellular matrix. Because CD138 is highly expressed on MM cells, it is considered an attractive target. In 2016, a group at the Chinese PLA General Hospital reported on the treatment of chemotherapy-refractory MM with a CD138 (CART138)-directed 4-1BBζ CAR construct [26] . Five patients received 3-6 CART138 injections following various combinations of pre-conditioning/induction therapy. Four out of the five patients experienced mild fever, attributed to the second injection of CAR T cells. Four of the five patients achieved stable disease (SD) ranging from 3 to 7 months; CAR T cells were detected in bone marrow for upwards of 3 months. The fifth patient experienced PD and was transitioned to palliative care, despite detectable CART138 cells in bone marrow for 90 days. Data from this study are limited and should be interpreted cautiously. Despite the attractiveness of CD138 as a target for MM, it does have potential drawbacks. First, CD138 is known to be expressed on epithelial tissues, and prior clinical trials investigating an anti-CD138-antibody drug-conjugate in MM treatment were notable for skin and/or mucosal toxicity (e.g., mucositis, stomatitis, hand/foot syndrome). Second, CD138 is shed from malignant cells thereby acting as a potential decoy for CD138-targeted T cells. Future studies targeting CD138 with CAR T cells may need to include strategies to avoid on-target toxicity while maintaining potential anti-tumor effects [33] .
Kappa-Light Chain
Given that mature B lymphocytes express either κ or λ light chains, but not both, Ramos et al. [27••] recently developed a kappa-specific CAR construct that could recognize kappa-restricted cells, while leaving the lambda-restricted subset intact, thereby maintaining at least partial humoral immunity. Although plasma cells do not express surface immunoglobulins (Igs), they reasoned that targeting the kappa-light chain may also be applicable to MM as several groups have described an MM-initiating population that expresses surface Igs [27••] . In their phase I clinical trial, seven MM patients were treated with a 2 ndgeneration CD28-CD3ζ CAR T cell construct against the κ light chain (κ.CARTs). Patients received 1-2 infusions of κ.CARTs with a 50% reduction in the number of circulating B cells within the first 2 weeks of treatment. Encouragingly, the elimination of B cells was primarily of κ light chain origin. Four of seven MM patients experienced responses to infused κ.CARTs, with stable disease (>24 months), minimal residual disease, or overall improvement of disease symptoms. More robust responses were seen in the CLL and NHL patients likely due to their higher surface expression of κ light chain. The CAR T cell product was well tolerated, and none of the patients experienced severe CRS.
BCMA
Recently, there has been much focus on the B cell maturation antigen (BCMA) as a CAR target in MM. To date, four clinical trials are registered in the USA using various CAR T cell products against BCMA. BCMA is a cell surface protein exclusively expressed on the B cell linage and is involved in the differentiation and maturation of B cells into plasma cells. BCMA is highly expressed on malignant MM plasma cells and provides a substantial anti-apoptotic signal making it an encouraging target for BCMA-directed immunotherapy. The first results from a clinical trial, utilizing a 2 nd -generation anti-BCMA-CAR with CD28, was published by Ali et al., in 2016. The trial was designed as a phase I dose-escalation trial, with 12 patients receiving either 0.3, 1, 3, or 9 × 10 6 ]CAR-positive T cells per kg. Prior to CAR T cell infusion, the patients received lymphodepletion therapy (3 × 300 mg/m 2 cyclophosphamide and 3 × 30 mg/m 2 fludarabine). The higher-dose cohorts experienced more pronounced adverse effects attributed to CAR T cells, including CRS. CAR-BCMA-positive cells were detected in the blood of all patients in a dose-dependent manner. Responses included a stringent CR (n = 1), VGPR (n = 2), PR (n = 1), and SD (n = 8) for up to 16 weeks. The best responses occurred in the highest-dose cohorts. Despite the concern for possible antigenic loss of BCMA following CAR T cell therapy, only one Fig. 1 Comparative description of CAR T cell strategies that have been used as immunotherapies against multiple myeloma patient in the CAR-BCMA study was reported to relapse with BCMA-negative MM clones in the bone marrow [28•] .
Two other BCMA-CAR products are currently being tested in clinical trials. Data from these trials were presented at the recent ASH meeting in 2016. Cohen et al., from the University of Pennsylvania, presented data from an ongoing phase I dose-escalation study, with a 2 nd -generation 4-1BB-CD3ζ anti-BCMA-CAR. To date, six patients received CART-BCMA cells as split dose infusions (10% at day 0, 30% at day 1, and 60% at day 2). Five patients experienced CRS toxicity, with two patients requiring tocilizumab treatment. Interestingly, the two patients receiving tocilizumab had only received 40% of the planned CAR T cell dose due to fever. These patients experienced a robust anti-tumor response as demonstrated by a stringent CR and VGPR despite administration of tocilizumab and incomplete infusion of the targeted CAR T cell dose. CART-BCMA cells were detected in both blood and bone marrow by PCR, with persistence reported for up to 7 months for the patient experiencing CR. Five months after therapy, the patient achieving a VGPR progressed, associated with a reduction in circulating CART-BCMA cells. Further analysis identified loss of BCMA expression on malignant cells, indicative of antigen escape. The remaining four patients experienced SD (n = 1), minimal response (n = 2), or PD (n = 1), with minimal expansion of CART cells correlating to poorer responses [29] . This same group also recently published a case report of posterior reversible encephalopathy syndrome (PRES) after infusion of anti-BCMA-CAR T cells. They reported on a 55-year-old female with high-risk IgA lambda MM who developed worsening neurological toxicity requiring intubation following CAR T cell infusion despite treatment with tocilizumab and high-dose steroids; treatment with cyclophosphamide reversed the syndrome. The rapid reversibility and MRI appearance was felt to be most consistent with PRES. They postulated that high CSF levels of CRS-related cytokines may have caused the syndrome. Additionally, they demonstrated that cyclophosphamide may effectively reverse life-threatening, steroid-refractory CAR T cell neurotoxicity while retaining some CAR T cell efficacy and long-term persistence [34] .
Blubird Bio reported data in December 2016, from a cohort of nine patients with relapsed/refractory MM who received infusion of an anti-BCMA-CAR product (bb2121). Bb2121 is a 2 nd -generation CAR T cell product with 4-1BB co-stimulation. Patients received a single infusion of bb2121 at various doses (5, 15, or 45 × 10 7 CAR T cells) after cyclophosphamide/fludarabine pre-conditioning. In all patients, CAR T cell expansion and persistence were observed, ranging from 4 to 24 weeks after infusion. The best response was achieved in the cohort treated with 15 × 10 7 CAR T cells, with two patients showing stringent CR and one patient VGPR. In the low-dose cohort, three patients initially achieved PR, SD, and PD, respectively. All the patients in this cohort experienced disease progression between 8 and 11 weeks post CAR infusion. Overall, BCMA as antigen target for CAR T-based immunotherapy seems promising with various clinical outcomes reflecting the various CAR construct designs, dose, and baseline disease burden. Further studies are warranted, to determine the best BCMA-CAR design for treatment of MM [35] .
Conclusion
In this review, we have outlined the recent clinical data with CAR T cells as they transition as a platform from targeting B cell malignancies to targeting multiple myeloma with a variety of antigen targets. Multiple questions remain, including a thorough understanding of the potential toxicities specific to multiple myeloma, including cytokine release syndrome, the depth and duration of antitumor effects, and the role that CAR T cells may play in the management of MM, where there are multiple therapies available. So far, CARs targeting BCMA seem to offer the most promise. As the field moves forward, new strategies to overcome the described limitations are being developed. With the introduction of dual-targeting CARs (e.g., iCAR or CARs recognizing two antigens), future treatment of MM with CAR T cell therapy may result in longer-lasting efficacy and avoid antigen escape. As in other hematologic diseases, antigen escape is emerging as a new hurdle and is likely due to the selective pressure exerted by CARs. Therefore, more research and development into the optimal CAR construct, with limited toxicities, no antigen escape, and high anti-tumor efficacy, is still needed. However, with combined efforts between academic institutions and their industry partners, CARs have the potential for offering definitive therapy for MM.
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